📊 CRDF Key Takeaways
Is Cardiff Oncology, Inc. (CRDF) a Good Investment?
Cardiff Oncology is a pre-revenue clinical-stage biotech company with severe cash burn (-$37.9M operating cash flow) and minimal revenue ($593K), indicating the company is not yet commercializing products effectively. With only 17.5 months of cash runway at current burn rates and no clear path to profitability, the company faces significant financial distress risk despite having zero debt.
Cardiff Oncology’s fundamentals remain very weak: revenue is minimal and declining, while operating and free cash flow losses are extremely large relative to its asset and equity base. The balance sheet has no long-term debt and acceptable near-term liquidity, but the current cash position appears insufficient against the company’s annual cash burn, making future dilution or external financing a central risk.
Why Buy Cardiff Oncology, Inc. Stock? CRDF Key Strengths
- Strong liquidity position with 3.67x current ratio providing near-term operational flexibility
- Zero long-term debt eliminates financial leverage risk and provides balance sheet flexibility
- Positive equity cushion of $45.4M provides some buffer against losses
- Debt-free balance sheet with no long-term debt
- Current and quick ratios of 3.67x support near-term obligations
- Net loss was roughly flat year over year and diluted EPS improved year over year
CRDF Stock Risks: Cardiff Oncology, Inc. Investment Risks
- Severe cash burn of $37.9M annually with only $17.5M cash on hand represents critical runway risk
- Revenue of $593K is negligible and declining 13.2% YoY, indicating failed commercialization or clinical translation
- Operating losses of $49.0M and negative net margin of -7732% demonstrate unsustainable unit economics with no viable business model
- Operating income of -$48.96M and free cash flow of -$37.97M indicate an unsustainable business model without new funding
- Cash and equivalents of $17.47M are low relative to operating cash burn of $37.92M
- Revenue fell 13.2% year over year and remains too small to support operations
Key Metrics to Watch
- Quarterly cash burn rate and cash runway remaining
- Revenue growth and drug pipeline advancement towards commercialization
- Clinical trial success rates and regulatory milestones for product candidates
- Cash runway relative to quarterly operating cash burn
- Progress in revenue generation and reduction in operating loss
Cardiff Oncology, Inc. (CRDF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.67x current ratio provides a solid financial cushion.
CRDF Profit Margin, ROE & Profitability Analysis
CRDF vs Healthcare Sector: How Cardiff Oncology, Inc. Compares
How Cardiff Oncology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cardiff Oncology, Inc. Stock Overvalued? CRDF Valuation Analysis 2026
Based on fundamental analysis, Cardiff Oncology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cardiff Oncology, Inc. Balance Sheet: CRDF Debt, Cash & Liquidity
CRDF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cardiff Oncology, Inc.'s revenue has grown significantly by 87% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.95 indicates the company is currently unprofitable.
CRDF Revenue Growth, EPS Growth & YoY Performance
CRDF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $120.0K | -$10.0M | $-0.17 |
| Q2 2025 | $121.0K | -$10.0M | $-0.21 |
| Q1 2025 | $109.0K | -$10.0M | $-0.20 |
| Q3 2024 | $141.0K | -$9.7M | $-0.22 |
| Q2 2024 | $108.0K | -$10.0M | $-0.25 |
| Q1 2024 | $83.0K | -$10.0M | $-0.22 |
| Q3 2023 | $93.0K | -$8.6M | $-0.20 |
| Q2 2023 | $91.0K | -$10.4M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cardiff Oncology, Inc. Dividends, Buybacks & Capital Allocation
CRDF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cardiff Oncology, Inc. (CIK: 0001213037)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRDF
What is the AI rating for CRDF?
Cardiff Oncology, Inc. (CRDF) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRDF's key strengths?
Claude: Strong liquidity position with 3.67x current ratio providing near-term operational flexibility. Zero long-term debt eliminates financial leverage risk and provides balance sheet flexibility. ChatGPT: Debt-free balance sheet with no long-term debt. Current and quick ratios of 3.67x support near-term obligations.
What are the risks of investing in CRDF?
Claude: Severe cash burn of $37.9M annually with only $17.5M cash on hand represents critical runway risk. Revenue of $593K is negligible and declining 13.2% YoY, indicating failed commercialization or clinical translation. ChatGPT: Operating income of -$48.96M and free cash flow of -$37.97M indicate an unsustainable business model without new funding. Cash and equivalents of $17.47M are low relative to operating cash burn of $37.92M.
What is CRDF's revenue and growth?
Cardiff Oncology, Inc. reported revenue of $593.0K.
Does CRDF pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
Where can I find CRDF SEC filings?
Official SEC filings for Cardiff Oncology, Inc. (CIK: 0001213037) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRDF's EPS?
Cardiff Oncology, Inc. has a diluted EPS of $-0.69.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CRDF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cardiff Oncology, Inc. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CRDF stock overvalued or undervalued?
Valuation metrics for CRDF: ROE of -101.0% (sector avg: 15%), net margin of -7,732.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CRDF stock in 2026?
Our dual AI analysis gives Cardiff Oncology, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CRDF's free cash flow?
Cardiff Oncology, Inc.'s operating cash flow is $-37.9M, with capital expenditures of $44.0K. FCF margin is -6,402.5%.
How does CRDF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -7,732.0% (avg: 12%), ROE -101.0% (avg: 15%), current ratio 3.67 (avg: 2).